Trial Profile
Optimizing Abiraterone (Zytiga) Therapy by Exploring the Relation Between an Early Biomarker ‐ Drug Exposure ‐ as a Predictor for Drug Response in Patients With mCRPC
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary)
- Indications Prostate cancer
- Focus Biomarker; Pharmacokinetics
- Acronyms OPTIMUM
- 30 Mar 2023 Results investigated whether changes in circulating tumor DNA (ctDNA) fraction during ARPI treatment are linked with mCRPC clinical outcomes by collecting Plasma cell-free DNA from NCT02426333;NCT02471469, published in the Clinical Cancer Research
- 07 Jun 2022 Pooled results from NCT02426333 and NCT02471469 studies presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 26 Aug 2021 Data from three clinical studies (ANDROPS, OPTIMUM(NCT02426333) and SNACK(NCT02883166)) assessing whether the exposure-respone relation for abiraterone is different for pre-chemotherapy patients compared to post-chemotherapy patients with mCRPC